Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant’s top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.
The post Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda appeared first on MedCity News.
